<DOC>
	<DOCNO>NCT03087942</DOCNO>
	<brief_summary>The aim study ass whether renal impairment could affect fevipiprant pharmacokinetics ( PK ) extent dosage adjustment appropriate patient population . The study also aim determine effect dialysis fevipiprant pharmacokinetic profile procedure might remove significant fraction drug .</brief_summary>
	<brief_title>Pharmacokinetics Safety Fevipiprant Patients With Renal Impairment Compared Matched Healthy Subjects</brief_title>
	<detailed_description>The purpose study determine pharmacokinetic profile fevipiprant different patient renal impariment compare healthy match volunteer extent would require adjustment dosage . Data study use guide enrollment criterion future clinical trial support regulatory submission label information</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Indoleacetic Acids</mesh_term>
	<criteria>Healthy subject must satisfy criterion normal renal function evidence normal Glomerular Filtration Rate ( GFR ) : eGFR ≥ 90 mL/min/1.73m2 ; healthy subject must match age ( +/ 10years ) , gender , smoke status , weight ( +/ 15 % ) , patient renail impair patient group : A body mass index ( BMI ) within range 18 36 kg/m2 ESRD patient hemodialysis : glomerulo filtration rat GFR &lt; 15 mL/min/1.73 m2 patient severe renal impairment : GFR &lt; 30 mL/min/1.73m2 ( without need hemodialysis ) ; patient moderate renal impairment : 30 mL/min/1.73m2 ≤ eGFR &lt; 60 mL/min/1.73m2 ; patient mild impairment : 60 mL/min/1.73m2 ≤ eGFR &lt; 90 mL/min/1.73m2 Pregnant nursing ( lactate ) woman History evidence inherit bilirubin disease disorder subject participate another study malignancy past Hemoglobin level 10 g/dL screen HIV positiv Heavy smoker ( ≥20 cigarette per day ) Liver disease , indicate ALT , γGT , AST alkaline phosphatase exceed twice upper limit normal stable ( e.g . increase liver value know previous patient record ) . Serum bilirubin &gt; 27 μmol/L ( 1.6 mg/dL ) Clinically significant ECG change and/or arrhythmias Chronic infection Hepatitis B ( HBV ) Hepatitis C ( HCV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>end stage renal disase ESRD</keyword>
	<keyword>dialysis effect pharmacokinetics PK</keyword>
	<keyword>renal impairment</keyword>
</DOC>